Amylyx Pharmaceuticals (NASDAQ:AMLX) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Amylyx Pharmaceuticals (NASDAQ:AMLX) issued its quarterly earnings data on Tuesday. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.01, FiscalAI reports.

Here are the key takeaways from Amylyx Pharmaceuticals’ conference call:

• Enrollment for the pivotal LUCIDITY Phase 3 trial is complete, the open‑label extension is underway, and management expects top‑line results in Q3 2026.
• Amylyx ended Q4 with $317 million in cash and marketable securities, which management says provides a cash runway into 2028 to fund key milestones including the LUCIDITY readout and potential launch activities.
• The company is actively preparing an NDA and building commercial and medical infrastructure now to support a potential 2027 commercialization of avexitide if approved, including market research, KOL engagement, and payer strategy work.
• Pipeline progress: Amylyx nominated AMX0318 (a long‑acting GLP‑1 receptor antagonist) as a development candidate with IND‑enabling work underway targeting an IND in 2027, and AMX0114 advanced in the Phase 1 ALS LUMINA trial with cohort enrollment ongoing.
• Management modeled conservative powering assumptions for LUCIDITY (including up to a 50% placebo effect and 35% effect vs placebo) despite prior trials showing low placebo response, underscoring trial outcome uncertainty and regulatory risk.

Amylyx Pharmaceuticals Trading Up 6.7%

Shares of AMLX opened at $15.05 on Thursday. The business’s 50 day moving average is $13.88 and its 200 day moving average is $13.17. Amylyx Pharmaceuticals has a 12-month low of $3.00 and a 12-month high of $17.49. The company has a market capitalization of $1.65 billion, a PE ratio of -9.71 and a beta of -0.31.

Insiders Place Their Bets

In related news, Director Karen Firestone bought 8,100 shares of the company’s stock in a transaction that occurred on Tuesday, December 23rd. The stock was purchased at an average price of $12.45 per share, for a total transaction of $100,845.00. Following the completion of the transaction, the director owned 63,100 shares in the company, valued at $785,595. The trade was a 14.73% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Joshua B. Cohen sold 136,193 shares of Amylyx Pharmaceuticals stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $13.59, for a total transaction of $1,850,862.87. Following the completion of the sale, the chief executive officer owned 3,378,621 shares in the company, valued at approximately $45,915,459.39. This represents a 3.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 151,203 shares of company stock valued at $2,028,385. 12.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Meeder Asset Management Inc. bought a new position in Amylyx Pharmaceuticals during the fourth quarter valued at $25,000. California State Teachers Retirement System bought a new stake in shares of Amylyx Pharmaceuticals in the 2nd quarter valued at approximately $28,000. Legal & General Group Plc purchased a new position in Amylyx Pharmaceuticals during the second quarter worth $47,000. BNP Paribas Financial Markets boosted its stake in shares of Amylyx Pharmaceuticals by 433.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company’s stock worth $47,000 after purchasing an additional 5,904 shares during the period. Finally, Caitong International Asset Management Co. Ltd boosted its position in shares of Amylyx Pharmaceuticals by 1,116.9% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,454 shares of the company’s stock valued at $54,000 after buying an additional 4,088 shares during the period. 95.84% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Bank of America upped their price target on Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the stock a “buy” rating in a research report on Friday, February 20th. Wall Street Zen lowered shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Stifel Nicolaus began coverage on shares of Amylyx Pharmaceuticals in a research note on Tuesday. They set a “buy” rating and a $21.00 target price on the stock. HC Wainwright lifted their price target on shares of Amylyx Pharmaceuticals from $28.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Monday, December 29th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $19.56.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.